Dr. Keith Stockerl-Goldstein
Claim this profileWashington University School of Medicine
About Keith Stockerl-Goldstein
Education:
- Obtained a BA in Biology from Washington University, Saint Louis, Missouri, 1986.
- Earned an MD from the University of California Los Angeles (UCLA) School of Medicine, 1991.
- Completed Residency in Internal Medicine at Stanford University Hospital, 1993.
- Undertook Fellowships in Bone Marrow Transplantation (1995) and Medical Oncology (1996) at Stanford University School of Medicine.
Experience:
- Former Clinical Director of Adult Bone Marrow Transplantation Unit at Stanford University School of Medicine.
- Currently serves as Program Director for Hematology-Medical Oncology & Hematology Focused Fellowship Training Program at Washington University School of Medicine.
- Holds the position of Associate Program Director for Bone Marrow Transplantation at the same institution.
Area of expertise
Multiple Myeloma
Keith Stockerl-Goldstein has run 13 trials for Multiple Myeloma. Some of their research focus areas include:
Acute Myelogenous Leukemia
Keith Stockerl-Goldstein has run 8 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:
Affiliated Hospitals
Washington University School Of Medicine
Siteman Cancer Center-South County
Clinical Trials Keith Stockerl-Goldstein is currently running
Dendritic Cells
for Graft-versus-Host Disease
Dendritic cells (DCs) serve as sentries for the immune system. DCs recognize foreign compounds (antigens) in the body, which they internalize and process. When DCs uptake foreign antigens, they migrate to secondary lymphoid organs, where the processed antigens are presented to T cells. Various DC subsets with unique cell lineages, surface protein markers, and tissue localization determinants have been identified. For example, Langerhans cells (LCs) and interstitial dendritic cells (intDCs) are DCs found in stratified epithelia, such as the skin. Though both are expressed in the skin, they differ with respect to their origin and surface protein content and can activate distinct types of immune responses. They may also have different specificities for the capture of antigens and presentation to circulating T cells. To date, it is unknown what role, if any, the different DC populations that reside or repopulate in the skin play in the development and progression of skin graft-versus-host disease (GVHD) following bone marrow transplant.
Recruiting
1 award
N/A
3 criteria
64Cu-LLP2A Imaging
for Blood Cancers
This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.
Recruiting
1 award
Phase < 1
4 criteria
More about Keith Stockerl-Goldstein
Clinical Trial Related
1 year of experience running clinical trials · Led 28 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Keith Stockerl-Goldstein has experience with
- Lenalidomide
- Dexamethasone
- Daratumumab
- Bortezomib
- Melphalan
- Isatuximab
Breakdown of trials Keith Stockerl-Goldstein has run
Multiple Myeloma
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Graft-versus-Host Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Keith Stockerl-Goldstein specialize in?
Keith Stockerl-Goldstein focuses on Multiple Myeloma and Acute Myelogenous Leukemia. In particular, much of their work with Multiple Myeloma has involved Stage IV patients, or patients who are Stage III.
Is Keith Stockerl-Goldstein currently recruiting for clinical trials?
Yes, Keith Stockerl-Goldstein is currently recruiting for 7 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Keith Stockerl-Goldstein has studied deeply?
Yes, Keith Stockerl-Goldstein has studied treatments such as Lenalidomide, Dexamethasone, Daratumumab.
What is the best way to schedule an appointment with Keith Stockerl-Goldstein?
Apply for one of the trials that Keith Stockerl-Goldstein is conducting.
What is the office address of Keith Stockerl-Goldstein?
The office of Keith Stockerl-Goldstein is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.